AGILERA PHARMA AS: årsregnskap 2025 vs 2024
Weaker earnings, fresh owner capital
approved 2026-04-07; registry 2026-07-13; journal 2026 571012
Summary
What changed
Comparing Årsregnskap 2025 with 2024 for AGILERA PHARMA AS. Revenue 357.64m NOK → 352.52m NOK (-1.4%). Net result -34.75m NOK → -69.62m NOK. Equity 15.02m NOK → 18.46m NOK.
On the constructive side: equity strengthened; owners injected capital. Pressures included: revenue fell; operating result weakened; net result weakened.
Also worth watching: thin equity buffer; cogs fell. All figures are taken from the published annual accounts for AGILERA PHARMA AS.
At a glance
Scorecard
What improved
-
↑
Equity strengthened
Book equity 15.02m NOK → 18.46m NOK (equity ratio 10.1% → 10.0%). Calculated
-
↑
Owners injected capital
Paid-in equity rose 15.02m NOK → 88.08m NOK (+73.06m NOK). Reported fact
What deteriorated
-
↓
Revenue fell
Operating income / revenue moved from 357.64m NOK to 352.52m NOK (-1.4% YoY). Calculated
-
↓
Operating result weakened
Operating result -28.99m NOK → -63.97m NOK (op. margin -8.1% → -18.1%). Calculated
-
↓
Net result weakened
Net result -34.75m NOK → -69.62m NOK (net margin -9.7% → -19.7%). Calculated
-
↓
Cash fell
Bank deposits 19.09m NOK → 11.67m NOK (-38.9% YoY). Calculated
-
↓
Payroll up without matching revenue
Salary cost 4.10bn NOK → 4.13bn NOK (1148% → 1172% of revenue). Calculated
Things to notice
-
·
Thin equity buffer
Equity ratio is 10.0% of assets — limited loss-absorbing capacity on a stand-alone basis. Interpretation
-
·
COGS fell
COGS / varekostnad 2.20bn NOK → 2.19bn NOK (-0.1% YoY). Calculated